• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX

    4/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    Industry leading set of technologies to drive scalability, flexibility, and efficiency in biologics production

    RADNOR, Pa., April 1, 2025 /PRNewswire/ -- Avantor®, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals. The company will showcase fluid handling technologies that support every step of the bioprocessing continuum, delivering exceptional scalability, flexibility, and efficiency in media and buffer preparation, filtration, purification, and final formulation applications.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    "Avantor's participation at INTERPHEX is an exciting opportunity for us to showcase technologies that redefine how biomanufacturers manage their fluid handling operations," said Benoit Gourdier, Executive Vice President, Bioscience Production at Avantor. "We're excited to connect with customers and attendees in New York City and demonstrate how our fluid handling solutions address their most complex production challenges."

    Attendees are invited to experience personalized product demonstrations with Avantor's Magnetic Mixing Systems, the MasterSense™ smart ecosystem for Masterflex® peristaltic pumps, J.T.Baker® Direct Dispense Systems for buffer management, and customizable solutions for tangential flow filtration. Avantor's approach to fluid handling solutions provides biopharma manufacturers with unprecedented choice to match their unique bioprocessing needs. Avantor will be exhibiting at booth #3843.

    Avantor's Magnetic Mixing Systems ensure homogeneous mixing with minimal shear, protecting sensitive biologics in a single-use, closed system. The new 10L tabletop system, along with the 200L showcased at INTERPHEX, joins Avantor's scalable family of mixers that extend up to 1500L, offering consistent and accurate mixing performance across various batch sizes and production demands. Developed for full single-use applications and customizable to exacting specifications, the mixers easily scale from process development to commercial production.

    Supporting aseptic and seamless fluid transfer, Avantor will demonstrate the Masterflex MasterSense pump system's smart, digital ecosystem built for precision and repeatability. With scalable pump sizes, intuitive protocol programming and real-time fluid pressure monitoring, MasterSense enables researchers and manufacturers to streamline tasks and save valuable time across fluid volumes.

    Across its portfolio, Avantor prioritizes flexible implementation and modularity to meet the unique needs of single-use, multi-product, and hybrid facilities. Avantor is committed to advancing bioprocessing through innovative, end-to-end fluid handling solutions.

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development, and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter), and Facebook.

    About INTERPHEX

    INTERPHEX is the premier pharmaceutical, biotechnology, and device development and manufacturing event where you can "Experience Science through Commercialization." The event is based in New York and brings approximately 9,000 global industry professionals and industry leading suppliers together to "Learn it, Experience it, Procure it" through a unique combination of exhibits, demonstrations, partnering opportunities, networking and INTERPHEX Conference in the Learning Lab to leverage quality, efficiency, and cost effectiveness in today's ever-changing global market. INTERPHEX offers annual domestic and international industry events and educational opportunities around the world. For more information, visit www.INTERPHEX.com.

    Global Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected] 

    Investor Relations Contact

    Allison Hosak

    Senior Vice President, Global Communications

    Avantor

    908-329-7281

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-showcases-scalable-fluid-handling-innovations-at-interphex-302416353.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    More analyst ratings

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Reiterates Shareholder Value Creation Focus

    Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to Begin Role as CEO Next Week RADNOR, Pa., Aug. 11, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today issued the following statement in response to the letter issued by Engine Capital:  The Board of Directors is actively engaged in overseeing the setting and execution of the Company's strategy and is committed to always acting in the best inter

    8/11/25 9:33:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Engine Capital Sends Letter to Avantor's Board of Directors Regarding Opportunities to Improve Governance and Unlock Shareholder Value

    Believes Years of Self-Inflicted Issues Have Caused Avantor to Trade at a Meaningful Discount to its Intrinsic Value and Life Sciences Peers Contends the Board Has Failed to Remedy Operating Underperformance, Ineffective Cost Controls and Poor Capital Deployment – Resulting in Significant Value Destruction Over Every Relevant Period Makes Clear the Board Needs to Be Refreshed with New Directors with Successful Experience in Healthcare Distribution, Capital Allocation and Leadership at Relevant Companies Sees Path to Realizing 100% Upside in Share Price by End of 2027 by Prioritizing Cost Discipline, Operational Improvements, Portfolio Optimization and Immediate Share Repurchases Eng

    8/11/25 7:00:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/22/25 5:37:34 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/9/25 4:51:58 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AVTR
    SEC Filings

    View All

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Avantor downgraded by Jefferies

    Jefferies downgraded Avantor from Buy to Hold

    8/1/25 1:45:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Goldman with a new price target

    Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

    4/29/25 8:05:35 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by TD Cowen with a new price target

    TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

    4/28/25 8:32:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    8/13/25 5:03:52 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Avantor Inc.

    SCHEDULE 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/13/25 4:58:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    8/1/25 9:00:18 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.11% to 171,563 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/15/25 4:35:16 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, AMEA Couturier Christophe was granted 65,217 shares, increasing direct ownership by 45% to 211,271 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/12/25 5:04:18 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP & Chief Accounting Officer Eck Steven W sold $39,592 worth of shares (3,476 units at $11.39), decreasing direct ownership by 6% to 55,068 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/6/25 4:32:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

    NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

    7/23/24 7:17:00 PM ET
    $APO
    $AVTR
    $HIBB
    Investment Managers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Announces Emmanuel Ligner as Next President and CEO

    Seasoned Executive with Proven Track Record of Value Creation in Life Sciences RADNOR, Pa., July 21, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025. Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointme

    7/21/25 7:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Second Quarter 2025 Earnings Call on Friday, August 1, 2025

    RADNOR, Pa., June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the

    6/27/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials